Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study [0.03%]
基于注册表的描述性研究：血清肿瘤标志物动力学作为非小细胞肺癌化疗免疫治疗和单纯免疫治疗维持阶段的预测生物标志物
David Lang,Wolfgang Haslinger,Kaveh Akbari et al.
David Lang et al.
Objective: To evaluate serum tumor markers (STM) as predictive biomarkers in advanced non-small cell lung cancer (NSCLC) treated with chemo-immunotherapy. ...
Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer [0.03%]
质子治疗治疗地面玻璃阴影型肺癌的临床疗效分析
Ichiro Nagata,Takashi Ogino,Takeshi Arimura et al.
Ichiro Nagata et al.
Purpose: Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC), including ground-glass opacity (GGO)-type lung cancer. However, some patients are inoperable or refuse to undergo surgery. To ...
A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity [0.03%]
表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌中的当代文献综述及其毒性反应
Chung-Shien Lee,Sandhya Sharma,Emily Miao et al.
Chung-Shien Lee et al.
Mutations in the epidermal growth factor receptor (EGFR) are common amongst those with non-small cell lung cancer and represent a major factor in treatment decisions, most notably in the advanced stages. Small molecule tyrosine kinase inhib...
Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations [0.03%]
EGFR和MAPK共突变患者中有利于免疫的微环境
Wang Yang,Naifei Chen,Lingyu Li et al.
Wang Yang et al.
Purpose: Although EGFR-mutated patients generally do not benefit from checkpoint inhibitors (ICIs), some patients in the KEYNOTE-001 study consistently benefited from this treatment. This study investigated immune microen...
Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer [0.03%]
派姆单抗单药治疗非小细胞肺癌患者时免疫相关不良事件与疗效的关系研究
Susumu Noguchi,Keiichiro Suminaga,Takahiro Kaki et al.
Susumu Noguchi et al.
Purpose: The effects of immune checkpoint inhibitors have been reported to be linked with immune-related adverse events (irAEs). In patients with advanced non-small-cell lung cancer, who tested positive for programmed dea...
Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature [0.03%]
依维莫司在肺神经内分泌肿瘤治疗中的临床评估：患者选择及特殊考虑。系统的文献批判性回顾
Marta Peri,Nicola Fazio
Marta Peri
Neuroendocrine tumors (NETs) of the lung are well-differentiated neuroendocrine neoplasms (NENs) with a heterogeneous clinical behaviour. Unlike gastroenteropancreatic NENs where therapeutic armamentarium clearly increased over the last dec...
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors [0.03%]
携带ALK基因内部倒位或缺失重排的非小细胞肺癌患者的ROS1激酶抑制剂治疗反应持久
Alexa B Schrock,Russell Madison,Mark Rosenzweig et al.
Alexa B Schrock et al.
Background: ALK fusions are targetable drivers in non-small-cell lung cancer (NSCLC). However, patients with NSCLC harboring ALK rearrangements without a fusion partner identified in DNA have also been shown to respond to...
Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin [0.03%]
用于小细胞肺癌治疗的在研孤儿药Lurbinectedin的新进展
Diego Kauffmann-Guerrero,Rudolf Maria Huber
Diego Kauffmann-Guerrero
Lung cancer is the leading cause of death of all cancer entities and small-cell lung cancer (SCLC) is the most malignant subtype. Despite good initial response to chemotherapy, many patients relapse early and success of second line treatmen...
Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients [0.03%]
ROS1重排非小细胞肺癌在印度的发病情况及克唑替尼治疗肺腺癌患者的疗效
Anurag Mehta,Mumtaz Saifi,Ullas Batra et al.
Anurag Mehta et al.
Background: The ROS1 gene is a member of the "sevenless" subfamily of tyrosine-kinase insulin-receptor genes. ROS1-fusion rearrangement causes constitutive downstream signal transduction, with an oncogenic role in non-sma...
Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives [0.03%]
不可切除III期非小细胞肺癌免疫检查点抑制剂治疗新进展及展望
Hiroyuki Inoue,Isamu Okamoto
Hiroyuki Inoue
There has been no improvement in outcome for patients with unresectable locally advanced (stage III) non-small cell lung cancer (NSCLC) for more than 10 years. The standard treatment for these patients is definitive concurrent chemotherapy ...